Pharmaceutical Development Company Announces Promising Preclinical Results For Marijuana Analog
Promising Preclinical Findings of MIRA-55: A Potential Therapeutic Breakthrough.
MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA), a pre-clinical-stage pharmaceutical development company, recently announced promising new findings from its preclinical studies on MIRA-55, a novel oral pharmaceutical marijuana analog. This compound is being studied for its potential to treat anxiety and cognitive decline. Following this announcement, MIRA's stock saw a massive rise, reflecting investor optimism about the future potential of the compound. $MIRA Pharmaceuticals(MIRA.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
